Nivolumab-related mucous membrane pemphigoid

Dermatologic immune-related adverse events (IRaes) are among the most frequent toxicities reported with anti –programmed cell death (PD)-1 or anti–programmed cell death ligand (PD-L1) therapies, affecting up to 40% of treated patients [1,2]. They have been associated with a variety of dermatologic manifestations including eczema-like rash, pruritus, lichenoid reactions, induction or reactivation of pre existing psoriasis, vitiligo and granulomatous reactions [3]. They may also induce or reactivate autoimmune skin diseases [4].
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research